Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H29NO2 |
Molecular Weight | 339.4712 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)C(C(=O)C2=CN(CC3CCOCC3)C4=CC=CC=C24)C1(C)C
InChI
InChIKey=NQTMRZNYLIGQCF-UHFFFAOYSA-N
InChI=1S/C22H29NO2/c1-21(2)20(22(21,3)4)19(24)17-14-23(13-15-9-11-25-12-10-15)18-8-6-5-7-16(17)18/h5-8,14-15,20H,9-13H2,1-4H3
Molecular Formula | C22H29NO2 |
Molecular Weight | 339.4712 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17965748
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17965748
A-834735 is a drug developed by Abbott Laboratories, acts as a potent cannabinoid receptor full agonist at both the CB1 and CB2 receptors.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17965748
Curator's Comment: Known to be CNS active in rat. Human data not available
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P21554|||Q5UB37 Gene ID: 1268.0 Gene Symbol: CNR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17965748 |
4.6 nM [Ki] | ||
Target ID: P34972 Gene ID: 1269.0 Gene Symbol: CNR2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17965748 |
0.31 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. | 2008 Jan |
|
Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. | 2008 Jan |
|
Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. | 2010 Jan 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17965748
in rats: To benchmark imaging data against potential CNS side effects of A-834735 using traditional in vivo behaviour assays, rotarod performance and spontaneous exploratory behaviour were assessed in naive rats. Each rat was given three training sessions and then rotorod performance (mean latency to fall from the rotorod) was determined 30 min following i.p. administration of vehicle or A-834735 (0.5, 1.5 or 5 μmol kg−1). For spontaneous exploratory behaviour, a total of 40 rats (n=8 per group) were injected i.p. with vehicle (5% dimethyl sulphoxide/PEG400) or A-834735 (0.5, 1.5, 5 and 15 μmol kg−1) in a volume of 2 ml kg−1 and returned to their home cages.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17965748
Doses of A-834735 that produce CB1-mediated changes in brain activity detected by phMRI produce sufficient brain concentrations to bind CB1 and CB2 receptors and induce a functional effect, as predicted by in vitro Ki and EC50 data in binding and cAMP assays. A-834735 acts as a full agonist at both the central CB1 and peripheral CB2 receptors in rat with Ki values of 4.6 and 0.31 nM, respectively and EC50 values of 12 and 0.21 nM, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:25:24 GMT 2023
by
admin
on
Sat Dec 16 10:25:24 GMT 2023
|
Record UNII |
XE27L67C93
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11544639
Created by
admin on Sat Dec 16 10:25:24 GMT 2023 , Edited by admin on Sat Dec 16 10:25:24 GMT 2023
|
PRIMARY | |||
|
895155-57-4
Created by
admin on Sat Dec 16 10:25:24 GMT 2023 , Edited by admin on Sat Dec 16 10:25:24 GMT 2023
|
PRIMARY | |||
|
A-834,735
Created by
admin on Sat Dec 16 10:25:24 GMT 2023 , Edited by admin on Sat Dec 16 10:25:24 GMT 2023
|
PRIMARY | |||
|
XE27L67C93
Created by
admin on Sat Dec 16 10:25:24 GMT 2023 , Edited by admin on Sat Dec 16 10:25:24 GMT 2023
|
PRIMARY | |||
|
DTXSID60468349
Created by
admin on Sat Dec 16 10:25:24 GMT 2023 , Edited by admin on Sat Dec 16 10:25:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
MRI Imaging studies with SD rats
IN-VIVO
Scientific Literature
|
||
|
ACTIVE MOIETY |
Cannabinoid 1 receptor (CB1) and Cannabinoid 2 receptor (CB2) agonist; Ki=0.21 nM (Human CB2) & 12 nM (Human CB1)
IN-VITRO
Ki
|